The questions that take an hour elsewhere — answered in one click.
TheraRadar is a competitive intelligence platform for pharma and biotech. Search any drug, company, or target — and get the answer with the live data behind it.
Questions TheraRadar answers
When does Keytruda’s patent expire?
Patent expiry dates, exclusivity windows, and biosimilar timelines from the Orange and Purple Books.
Open on TheraRadar →Any GLP-1 / obesity readouts coming up?
Search "obesity" or "GLP-1" in the filter box. Combine with sponsor (Lilly, Novo) for tighter cuts.
Open on TheraRadar →What’s reading out at AstraZeneca in the next 6 months?
Filter by sponsor → window: Next 6 months. Reveals their full near-term catalyst slate in one screen.
Open on TheraRadar →What drugs were approved this year?
Browse FDA approvals indexed by sponsor, indication, modality, and approval date.
Open on TheraRadar →What does the competitive landscape for IL-23 look like?
Approved drugs, pipeline assets, sponsors, and combination strategies for the IL-23 target.
Open on TheraRadar →What’s happening in cell & gene therapy?
CAR-T, AAV, CRISPR, and other CGT programs indexed by sponsor, modality, indication, and clinical phase.
Open on TheraRadar →Try any of these at theraradar.com →
Latest from TheraRadar Briefs
Long-form pharma intelligence, published weekly on our product.
IBD and Precision Medicine: Not Yet
Prometheus gave IBD its best shot at oncology-style patient selection: a companion diagnostic for its anti-TL1A drug, tulisokibart. Merck paid $10.8 billion, then built its Phase 3 trials to enroll everyone. The more crowded the anti-TL1A field gets, the stronger the case for a precision-medicine approach, even as the science has yet to deliver one.
Read on TheraRadar ↗When an IBD Trial Is Terminated, the Drug Usually Didn’t Fail
Of 214 industry IBD trials terminated or withdrawn over two decades, only ~23% stopped for efficacy or safety. The rest ran out of patients, money, or corporate priority — the trial failed, not the biology.
Read on TheraRadar ↗Same Mechanism, Different Trial: How the FDA Rejected Patisiran but Approved Vutrisiran
Alnylam's two siRNA drugs hit the same liver target. One failed an FDA review in 2023. Two years later the other was approved for both forms of ATTR amyloidosis. The mechanism didn't change. The trial design did.
Read on TheraRadar ↗Entyvio: The Only IBD Drug That Stays in the Gut
Eleven years after approval, Entyvio remains the only IBD drug that acts only in the gut — and two large pharma programs have failed trying to replicate it.
Read on TheraRadar ↗T-Cell Engagers: The Off-the-Shelf Alternative to CAR-T
One arm grabs the cancer cell. The other grabs a T-cell. The bispecific forces them together.
Read on TheraRadar ↗IGF-1R: 20 Years of Cancer Failures, Then a $2 Billion Eye Drug
Pfizer, Amgen, Lilly, Merck, and Astellas all failed at IGF-1R in cancer. Then a shelved Roche antibody became the only effective treatment for thyroid eye disease. Same receptor, completely different biology.
Read on TheraRadar ↗Live data from public sources
Built on FDA approvals, ClinicalTrials.gov, SEC filings, and the Orange and Purple Books. Used by business development, competitive intelligence, medical affairs, and translational research teams across pharma and biotech.